AB Science

AB Science Liabilities

The The Liabilities of AB Science (AB.PA) as of Sep 21, 2026 is 34.34 M EUR. In the previous year, The Liabilities was 46.93 M EUR — a change of -26.83% (lower).

Liabilities

34.34 MEUR

YoY

-26.83%

Last updated:

In 2026, AB Science's total liabilities amounted to 34.34 M EUR, a -26.83% difference from the 46.93 M EUR total liabilities in the previous year.

The AB Science Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
37.45 M EUR
Jan 1, 2019
44.57 M EUR
Jan 1, 2020
49.24 M EUR
Jan 1, 2021
44.47 M EUR
Jan 1, 2022
59.51 M EUR
Jan 1, 2023
46.51 M EUR
Jan 1, 2024
46.93 M EUR
Jan 1, 2025
34.34 M EUR
The AB Science Liabilities history
YEARLiabilitiesYoY
34.34 MEUR-26.83%
46.93 MEUR+0.90%
46.51 MEUR-21.85%
59.51 MEUR+33.83%
44.47 MEUR-9.68%
49.24 MEUR+10.47%
44.57 MEUR+19.00%
37.45 MEUR-6.05%
39.87 MEUR-6.67%
42.72 MEUR-14.29%
49.84 MEUR+6.13%
46.96 MEUR—
Access this data via the Eulerpool API
Get Free API Key

AB Science Stock analysis

What does AB Science do? AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing AB Science's Liabilities

AB Science's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AB Science's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing AB Science's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

AB Science's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in AB Science’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about AB Science stock

The Liabilities of AB Science is 34.34 M EUR in 2026.

The Liabilities of AB Science changed from 46.93 M EUR to 34.34 M EUR, representing a -26.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities AB Science since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's AB Science historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — AB Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — AB Science